Get the Stockscreener App
1,101.95
0.97%
-10.05
Overview
News
Price History
Option Chain
Financials
Why LLY Down?
Discussions
Forecast
Stock Split
Dividend History
Lilly Eli Co stock is traded at $1,101.95, with a volume of 1.91M.
It is down -0.97% in the last 24 hours and up +11.45% over the past month.
Eli Lilly is a drug firm with a focus on neuroscience, cardiometabolic, cancer, and immunology. Lilly's key products include Verzenio and Jaypirca for cancer; Mounjaro, Zepbound, Foundayo, Jardiance, Trulicity, Humalog, and Humulin for cardiometabolic; and Taltz and Olumiant for immunology.
See More
Previous Close:
$1,112.00
Open:
$1120.49
24h Volume:
1.91M
Relative Volume:
0.61
Market Cap:
$982.48B
Revenue:
$72.25B
Net Income/Loss:
$25.28B
P/E Ratio:
39.67
EPS:
27.781
Net Cash Flow:
$10.37B
1W Performance:
-5.15%
1M Performance:
+11.45%
6M Performance:
+4.19%
1Y Performance:
+40.28%
1-Day Range:
$1,088.65
$1,122.33
1-Week Range:
$1,088.65
$1,169.99
52-Week Range:
$623.78
$1,182.73
Lilly Eli Co Stock (LLY) Company Profile
Name
Lilly Eli Co
Sector
Industry
Phone
(317) 276-2000
Address
LILLY CORPORATE CTR, INDIANAPOLIS, IN
Compare LLY vs JNJ, ABBV, NVS, MRK
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
LLY
Lilly Eli Co
|
1,101.75 | 991.62B | 72.25B | 25.28B | 10.37B | 27.78 |
JNJ
Johnson Johnson
|
229.65 | 563.77B | 96.36B | 21.04B | 17.80B | 8.6488 |
ABBV
Abbvie Inc
|
216.56 | 390.87B | 62.82B | 3.60B | 19.98B | 2.0274 |
NVS
Novartis Ag Adr
|
147.68 | 287.89B | 54.66B | 13.58B | 16.05B | 7.0171 |
MRK
Merck Co Inc
|
114.11 | 285.12B | 65.51B | 8.93B | 14.12B | 3.5532 |
Lilly Eli Co Stock (LLY) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-17-26 | Downgrade | HSBC Securities | Hold → Reduce |
| Feb-25-26 | Initiated | RBC Capital Mkts | Outperform |
| Feb-20-26 | Initiated | Barclays | Overweight |
| Jan-07-26 | Resumed | UBS | Buy |
| Dec-16-25 | Upgrade | Daiwa Securities | Neutral → Buy |
| Dec-15-25 | Reiterated | BofA Securities | Buy |
| Dec-15-25 | Reiterated | Goldman | Buy |
| Nov-13-25 | Initiated | Scotiabank | Sector Outperform |
| Nov-10-25 | Upgrade | Leerink Partners | Market Perform → Outperform |
| Oct-20-25 | Reiterated | BMO Capital Markets | Outperform |
| Oct-14-25 | Upgrade | Erste Group | Hold → Buy |
| Sep-17-25 | Downgrade | Berenberg | Buy → Hold |
| Aug-27-25 | Upgrade | HSBC Securities | Reduce → Hold |
| Aug-18-25 | Downgrade | Daiwa Securities | Outperform → Neutral |
| Aug-07-25 | Downgrade | Leerink Partners | Outperform → Market Perform |
| Jun-05-25 | Downgrade | Erste Group | Buy → Hold |
| Apr-28-25 | Downgrade | HSBC Securities | Buy → Reduce |
| Apr-22-25 | Initiated | Cantor Fitzgerald | Overweight |
| Dec-10-24 | Resumed | BofA Securities | Buy |
| Nov-15-24 | Initiated | Wolfe Research | Outperform |
| Oct-17-24 | Initiated | Bernstein | Outperform |
| Sep-13-24 | Resumed | Citigroup | Buy |
| Aug-12-24 | Upgrade | Deutsche Bank | Hold → Buy |
| Feb-21-24 | Downgrade | DZ Bank | Buy → Hold |
| Feb-16-24 | Reiterated | Morgan Stanley | Overweight |
| Dec-21-23 | Downgrade | Daiwa Securities | Buy → Outperform |
| Nov-09-23 | Initiated | Deutsche Bank | Hold |
| Oct-20-23 | Resumed | UBS | Buy |
| Aug-09-23 | Upgrade | Jefferies | Hold → Buy |
| Jul-26-23 | Reiterated | Citigroup | Buy |
| Jul-14-23 | Initiated | HSBC Securities | Buy |
| May-24-23 | Reiterated | BofA Securities | Buy |
| May-24-23 | Reiterated | UBS | Buy |
| Mar-13-23 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Mar-06-23 | Initiated | Jefferies | Hold |
| Feb-15-23 | Downgrade | Societe Generale | Hold → Sell |
| Nov-18-22 | Initiated | Credit Suisse | Outperform |
| Sep-22-22 | Upgrade | UBS | Neutral → Buy |
| May-23-22 | Initiated | SVB Leerink | Outperform |
| Apr-06-22 | Resumed | Morgan Stanley | Overweight |
| Mar-10-22 | Initiated | Daiwa Securities | Outperform |
| Jan-21-22 | Upgrade | DZ Bank | Hold → Buy |
| Jan-03-22 | Reiterated | Bernstein | Mkt Perform |
| Dec-17-21 | Initiated | Goldman | Neutral |
| Dec-16-21 | Reiterated | BMO Capital Markets | Outperform |
| Dec-16-21 | Reiterated | BofA Securities | Buy |
| Dec-09-21 | Resumed | Wells Fargo | Equal Weight |
| Nov-19-21 | Initiated | BMO Capital Markets | Outperform |
| Oct-11-21 | Upgrade | Berenberg | Hold → Buy |
| Sep-29-21 | Upgrade | Citigroup | Neutral → Buy |
| Aug-05-21 | Upgrade | DZ Bank | Hold → Buy |
| Jul-27-21 | Resumed | Truist | Buy |
| Jun-24-21 | Reiterated | Cantor Fitzgerald | Overweight |
| Jan-19-21 | Upgrade | Mizuho | Neutral → Buy |
| Dec-10-20 | Upgrade | Wolfe Research | Peer Perform → Outperform |
| Nov-10-20 | Resumed | Bernstein | Mkt Perform |
| Sep-29-20 | Initiated | Berenberg | Hold |
| Sep-03-20 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Jun-16-20 | Upgrade | Guggenheim | Neutral → Buy |
| Apr-21-20 | Downgrade | UBS | Buy → Neutral |
| Apr-09-20 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Feb-06-20 | Initiated | Mizuho | Neutral |
| Dec-18-19 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Oct-17-19 | Resumed | BofA/Merrill | Buy |
| May-28-19 | Initiated | Goldman | Buy |
| Apr-24-19 | Upgrade | Edward Jones | Hold → Buy |
| Apr-11-19 | Downgrade | Guggenheim | Buy → Neutral |
| Mar-12-19 | Initiated | JP Morgan | Overweight |
| Jan-23-19 | Initiated | UBS | Buy |
| Nov-26-18 | Downgrade | Citigroup | Buy → Neutral |
| Oct-31-18 | Upgrade | Credit Suisse | Underperform → Neutral |
| Oct-09-18 | Initiated | Guggenheim | Buy |
| Oct-01-18 | Reiterated | SunTrust | Buy |
| Sep-26-18 | Resumed | JP Morgan | Overweight |
View All
Lilly Eli Co Stock (LLY) Latest News
Chai Discovery Collaborates with Lilly TuneLab to Offer AI Capabilities to Select Biotechs - Business Wire
Charles River Joins Lilly TuneLab to Optimize AI/ML Platform through Nonclinical Testing Expertise - Business Wire
What’s Happening at Eli Lilly and Company (LLY)’s Pipeline? Early Signals Emerge - Yahoo Finance
Axcelead DDP Joins Lilly TuneLab to Advance AI Drug Discovery - Business Wire
Eli Lilly Urges Full Fed. Circ. To Scrap Teva's $177M IP Win - Law360
Eli Lilly (LLY) Sees Purchase of 41,000 Shares by ARK Investment - GuruFocus
Eli Lilly and Co (LLY) Stock Price, Trades & News - GuruFocus
Cathie Wood’s ARK sells Robinhood and Roku stock, buys Eli Lilly - Investing.com
Eli Lilly Stock's Trillion-Dollar Question - Yahoo Finance
Eli Lilly: Pharma With Unstoppable Momentum Targets Pain With Latest M&A Deal (NYSE:LLY) - Seeking Alpha
Everyone Is Watching Eli Lilly Stock's New Drugs. Here Is the Metric That Vanished - Yahoo Finance
FDA Approves New Eight-Week Maintenance Dosing Regimen for Eli Lilly’s (LLY) EBGLYSS - Yahoo
Eli Lilly buys 4E to deepen non-opioid pain push - The Pharma Letter
Parkland School Board will not provide tax break for Eli Lilly amid strained budget cycle - The Morning Call
Parkland School District rejects Eli Lilly tax break amid major budget challenges - WFMZ.com
[Latest] Global GLP-1 Receptor Agonist Market Size/Share Worth USD 95.3 Billion by 2035 at a 12.1% CAGR: Healthcare Foresights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth Rate, Value, SWOT Analysis) - GlobeNewswire Inc.
Can Retatrutide Extend Eli Lilly and Co (LLY)’s Lead in Weight Loss Market? - Yahoo Finance
Eli Lilly’s M&A spree continues with acquisition of non-opioid pain drugmaker 4E - Fierce Biotech
Lilly Acquires 4E Therapeutics To Advance Non-Opioid Chronic Pain Treatments - Pulse 2.0
Eli Lilly vs. Novo Nordisk: Better Obesity Drug Stock? - Yahoo Finance
Lilly Acquires 4E Therapeutics to Advance Non-Opioid Chronic Pain Pipeline - citybiz
Lilly buys non-opioid pain drugmaker 4E - BioPharma Dive
Eli Lilly’s hottest drugs face a quiet new threat - thestreet.com
Lilly buys another pain biotech; FDA sets decision for once-weekly PrEP pill - Endpoints News
Eli Lilly Acquires 4E Therapeutics for Undisclosed Amount >LLY - Moomoo
4E Therapeutics Acquired by Lilly to Advance Non-Opioid Approach to Chronic Pain - PR Newswire
Eli Lilly & Co. (NYSE:LLY): High Growth Momentum Meets Strong Technical Breakout Setup - ChartMill
Eli Lilly & Co (LLY) Gets a Buy from Barclays - The Globe and Mail
Eli Lilly Broadens Oncology Story With Jaypirca CLL Win And JAK2 Advance - simplywall.st
Lilly bet $2.3B on a Cambridge biotech and its first clinical trial just showed why - MassLive
GLP-1s, Eli Lilly to upgrade Alabama economy - The Business Journals
Early trial data points to Eli Lilly's AJ1-11095 in myelofibrosis - AD HOC NEWS
Why Eli Lilly's Oral Medicine Is Turning Heads? - Kalkine Media
Lilly Backs Abridge to Bring Ambient AI Into Clinical Trial Recruitment - AIM Media House
Lilly Sues Cipla to Block Copy of Breast Cancer Drug Verzenio - Bloomberg Law News
BMO reiterates Outperform on Eli Lilly stock, cites JAK2i data - Investing.com
BMO Capital Maintains Eli Lilly and Co(LLY.US) With Buy Rating, Maintains Target Price $1,300 - Moomoo
Is LLY Overvalued? DCF Says Worth $762 - GuruFocus
Barclays Maintains Eli Lilly and Co(LLY.US) With Buy Rating, Maintains Target Price $1,400 - Moomoo
Eli Lilly JAK2 Data Highlights Pipeline Beyond Obesity And Valuation Upside - Yahoo Finance
Eli Lilly (LLY) Reports Promising Phase 1 Study Results for New Myelofibrosis Treatment - GuruFocus
Eli Lilly (LLY) Reports Promising Phase 3 Trial Results for Jayp - GuruFocus
3 Reasons to Buy Eli Lilly Stock Like There's No Tomorrow - AOL.com
Eli Lilly & Co Shs Cert Deposito Arg Repr 0.14285714 Shs Trade Ideas — BCBA:LLY.CI - TradingView
Eli Lilly & Co. Stock (US5324571083): Weekly technical picture in focus - AD HOC NEWS
Lilly's Jaypirca significantly reduced the risk of disease progression or death by 45% when added to a venetoclax time-limited regimen in people with previously treated CLL/SLL - Investing News Network
Lilly's Jaypirca (pirtobrutinib) significantly reduced the risk of disease progression or death by 45% when added to a venetoclax time-limited regimen in people with previously treated CLL/SLL - investor.lilly.com
Eli Lilly and Company - Britannica
Eli Lilly & Co. Stock (US5324571083): Novo Nordisk peer check keeps obesity drug leader in focus - AD HOC NEWS
Is Eli Lilly (LLY) One Of The Most Profitable Blue Chip Stocks To Buy According To Hedge Funds? - Insider Monkey
Lilly trial drug cuts spleen size, symptoms in myelofibrosis - Stock Titan
Lilly Eli Co Stock (LLY) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.05%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):